These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 32729818)

  • 21. Consequences of endodontic treatment in primary teeth. Part I: A clinical and radiographic study of the influence of formocresol pulpotomy on the life-span of primary molars.
    van Amerongen WE; Mulder GR; Vingerling PA
    ASDC J Dent Child; 1986; 53(5):364-70. PubMed ID: 3463582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional anatomy of occipital lobe seizures: an experimental study in rats.
    Collins RC; Caston TV
    Neurology; 1979 May; 29(5):705-16. PubMed ID: 571569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial).
    Itano Y; Kato S; Tsuboi M; Kasuga H; Tsuruta Y; Sato F; Hishida M; Ishimoto T; Kosugi T; Ando M; Kuwatsuka Y; Maruyama S
    Kidney Int Rep; 2020 Dec; 5(12):2168-2177. PubMed ID: 33305109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
    Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
    Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
    Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etelcalcetide decreases the PTH-calcium setpoint without changing maximum and minimum PTH secretion in mice with primary hyperparathyroidism.
    Hayashi N; Imanishi Y; Hirakawa T; Kobayashi I; Tateishi T; Miyaoka D; Nagata Y; Mori K; Morioka T; Inoue A; Harada K; Inaba M; Emoto M
    J Bone Miner Metab; 2021 May; 39(3):430-438. PubMed ID: 33196900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease.
    Rodríguez-Ortiz ME; Rodríguez M
    F1000Res; 2020; 9():. PubMed ID: 32913635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
    Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics.
    Arenas MD; Rodelo-Haad C; de Mier MVP; Rodriguez M
    Clin Kidney J; 2021 Mar; 14(3):840-846. PubMed ID: 33777366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis.
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Prikoszovich T; Marculescu R; Beitzke D; Wielandner A; Erben RG; Oberbauer R
    Circ Res; 2021 May; 128(11):1616-1625. PubMed ID: 33825489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The therapeutic effect of plasma exchange on ANCA-associated vasculitis: A meta-analysis.
    Zhu Y; Rao J; Liu L; Ou J; Li W; Xue C
    Clin Nephrol; 2021 Jun; 95(6):312-322. PubMed ID: 33749583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
    Friedl C; Zitt E
    Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term efficacy and safety of etelcalcetide in hemodialysis patients with severe secondary hyperparathyroidism].
    Massimetti C; Tondo M; Feriozzi S
    G Ital Nefrol; 2020 Oct; 37(5):. PubMed ID: 33026204
    [No Abstract]   [Full Text] [Related]  

  • 35. Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials.
    Zhu Y; Ou J; Liu X; Xie Z
    Clin Nephrol; 2020 Oct; 94(4):173-180. PubMed ID: 32729818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
    Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
    JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.